Sio Gene Therapies, Inc. (SIOX) News

Sio Gene Therapies, Inc. (SIOX): $0.29

-0.03 (-8.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SIOX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 416

in industry

Filter SIOX News Items

SIOX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest SIOX News From Around the Web

Below are the latest news stories about Sio Gene Therapies Inc that investors may wish to consider to help them evaluate SIOX as an investment opportunity.

Insiders who bought stock earlier this year lose -US$183k as Sio Gene Therapies Inc. (NASDAQ:SIOX) drops to US$48m

The recent 10% drop in Sio Gene Therapies Inc.'s ( NASDAQ:SIOX ) stock could come as a blow to insiders who purchased...

Yahoo | February 21, 2022

Sio Gene Therapies (SIOX) Gets a Hold Rating from Leerink Partners

In a report issued on February 11, Mani Foroohar from Leerink Partners maintained a Hold rating on Sio Gene Therapies (SIOX – Research Report), with a price target of $1.00. The company's shares closed last Tuesday at $0.69, close to its 52-week low of $0.66. According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.0% and a 38.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and 4D Molecular Therapeutics.

Howard Kim on TipRanks | February 15, 2022

H.C. Wainwright Keeps Their Buy Rating on Sio Gene Therapies (SIOX)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sio Gene Therapies (SIOX – Research Report) today and set a price target of $7.00. The company's shares closed last Thursday at $0.80, close to its 52-week low of $0.75. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -14.3% and a 28.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Sio Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $5.00, representing a 525.0% upside.

Howard Kim on TipRanks | February 11, 2022

Sio Gene Therapies GAAP EPS of -$0.35 misses by $0.12

Sio Gene Therapies press release (SIOX): Q3 GAAP EPS of -$0.35 misses by $0.12.Cash and cash equivalents of $81.9M as of December 31, 2021 Shares -2.50% PM.

Seeking Alpha | February 11, 2022

Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results

Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease$81.9 million of cash and cash equivalents as of December 31, 2021, providing expected cash runway into calendar H2 2023 beyond the expected dates of major upcoming milestones for the AXO-AAV-GM1 and AXO-AAV-GM2 gene therapy programs NEW YORK and DURHAM, N.C., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene The

Yahoo | February 11, 2022

Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present data in an oral platform presentation and two poster presentations at the 18th Annual WORLDSymposium™ 2022, to be held February 7-11, 2022. Presentations will include an update on the Phase 1/2 trial of AXO-AAV-GM1, the co

Yahoo | February 2, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Rise and shine, trader!

William White on InvestorPlace | February 1, 2022

Sio Gene Terminates Parkinson''s Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition

Sio Gene Therapies Inc (NASDAQ: SIOX ) has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy program for Parkinson''s disease. Due to several factors, the Company is deprioritizing its Parkinson''s disease program, including resource requirements, development timelines to reach meaningful value inflection, and a challenging market and regulatory environment. Sio Full story available on Benzinga.com

Benzinga | February 1, 2022

Biofrontera, Synaptogenix top healthcare gainers; while Sio Gene, Anavex among losers

Biofrontera (BFRI) +14%. Synaptogenix (SNPX) +11%. Sio Gene Therapies (SIOX) -19%. Anavex Life Sciences (AVXL) -16%.

Seeking Alpha | February 1, 2022

Sio Gene announces resignation of CEO; ends licensing deal with Oxford Biomedica

Sio Gene Therapies (SIOX) is trading ~10% lower in the post-market after announcing the resignation of its CEO, Dr. Pavan Cheruvu.Dr

Seeking Alpha | January 31, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.658 seconds.